Within five years, a large number of original drugs will lose nearly 100 billion U.S. dollars due to the "patent cliff".

Pharmaceutical Network Market Analysis: Pharmaceutical industry's new drug research and development with long cycle, low success rate and large investment characteristics, often can successfully market a new drug requires a lot of manpower and material resources.
in order to get a corresponding return on investment, pharmaceutical companies often rely on the exclusive rights protected by the patents of drugs to gain a monopoly market.
, with the expiration of the patent period, generic drugs entered the market, the original pharmaceutical companies rely on monopoly sales revenue and profits showed a significant decline.
industry likens the phenomenon to a "patent cliff".
it is worth noting that in recent years, some market sales of large amounts of original drugs are facing a "patent cliff."
Truvada, Afinitor and Chantix are the top three expired drugs, according to Filec Pharma.
Truvada, is a conventional pill produced by Gilead Sciences that helps fight HIV.
was approved by the FDA in August 2004 to treat HIV-1 infection with other antiretroviral drugs, and in 2012 was approved by the FDA for sexually transmitted HIV-1 infection in adults.
But having been accused by Truvada of increasing unsafe behavior, Gilead initially did not promote Truvada's use for pre-exposure prevention, and it wasn't until the CDC formally recommended Truvada's use in 2014 that Gilead began to promote the condition.
is understood to have sales of nearly $3 billion in 2019.
industry believes that about $2 billion of that comes from pre-exposure prevention.
Afinitor has reached $1 billion in U.S. sales in 2019, officially becoming a heavyweight drug, according to a 2019 Annual Report released by Novartic.
In the Chinese market, Novartis' Afinitor has also been in the market for a long time, and in the 2019 revision of the new national health insurance directory, Ivemos has been included in the new health care catalog Category B as a negotiated drug renewal, and new reimbursement adaptations have been added.
Afinitor is facing a key competition from counterfeit products.
December 10, 2019, Endo's Par Pharmaceutical has been approved and launched 2.5 mg, 5 mg and 7 mg generic Afinitor ( Evimos).
, competition from other generics in the U.S. could begin in mid-2020.
ChantixChantix is Pfizer's Chantix star drug that affects nicotine in the body's brain and helps smokers quit smoking in two ways: to some extent, to play a nicotine-like role to relieve withdrawal symptoms that occur during the smoking cessation process;
has won several awards from the pharmaceutical industry for its efficacy.
has doubled since it was approved in the US in 2006.
2019, sales in the U.S. have reached $899 million.
In fact, in addition to the drugs above, according to Evaluate Pharma, patents for the original drug, which will have sales of nearly $159 billion in 2020-2024, are expected to result in a loss of about $94 billion in sales as a result of the expiration of the original drug's patents and the introduction of generics.
.